Communications Law
EU Study Reveals Positive Links Between Intellectual Property Ownership and Economic Performance
Happy Friday everybody! I just thought I would share an interesting article I came across this evening that briefs a recent report published by the European Union Intellectual Property Office. In 2015, a EUIPO study found that companies in the European Union with at least one patent, trademark or registered design “record higher revenues per employee […]
Scope of Official Mark Protection (and application of s. 12(1)(e))
The Federal Court Takes a Hard Look At Scope of Protection Available to An Official Mark This article stood out to me today after going through last week’s material on trademarks, especially since it has to do with the “controversial” category – official marks! As the article states, a mark that solely consists of an […]
Patent Troll Awarded $2.2 Billion Against Intel
Hey everyone, I came across this story and thought it would be interesting to share with everyone. The gist of it is that a company whose only business is buying old patents and prosecuting claimed infringements of them sued Intel for a cumulative $11 billion and this week a jury in Texas deliberated on two […]
News of the Week; February 24, 2021
INTELLECTUAL PROPERTY Canadian consultation on extending the general term of copyright open through March 12 Extra, extra, read all about it: new Canadian Bill proposes remuneration for use of journalistic works online Time to Pay the Copyright Piper? A Digital Media Platform Copyright Reckoning for Journalists is Upon Us! Meghan Markle gets summary judgment – […]
Should big pharma be allowed to keep their COVID vaccines patented?
https://www.businessinsider.com/vaccine-patents-ips-monopoly-vaccination-process-us-biden-africa-2021-2 There is a really interesting debate happening right now about whether COVID vaccines should have their patents lifted, to allow more production. It is estimated that the current vaccine production is only utilizing 43% of the world’s total vaccine production capabilities. Problematically, only 4% of doses are being administered in the global south (mainly […]